Open Access Articles- Top Results for Alcon
International Journal of Innovative Research in Science, Engineering and TechnologySPATIAL DISTRIBUTION OF HEAVY METAL CONCENTRATION IN GROUNDWATER IN AND AROUND PALK STRAIT SEA SHORE AREA USING GIS TECHNIQUES
International Journal of Innovative Research in Science, Engineering and TechnologySynthesis and Evaluation of Novel 1, 5- Benzothiazepine Derivatives as Anti- Inflammatory Agents
International Journal of Innovative Research in Science, Engineering and TechnologyTo Control Load Frequency by using Integral Controller
International Journal of Innovative Research in Science, Engineering and TechnologySynthesis Characterisation and Electrochemical Behaviour of 2-Hydroxy Chalcones using Silicagel Supported Piperidine
International Journal of Innovative Research in Science, Engineering and TechnologyCorrosion Inhibition of Aluminum in Hydrochloric Acid Solutions Using Some Chalcone Derivatives
|Traded as||NYSE: ACL|
|Fate||Acquired by Novartis|
|Founded||Fort Worth, Texas, United States (1945)|
Fort Worth, Texas, United States
|Kevin Buehler[dead link] President and CEO|
Contact care products
Dry Eye Products
|Revenue||11px $10 billion USD (2011)|
Number of employees
Alcon incorporated and with corporate headquarters, in Hünenberg, Switzerland, is a global medical company specializing in eye care products. Alcon's U.S. headquarters are located in Fort Worth, Texas. Alcon has been purchased by Novartis from Nestlé and there have been confirmed information indicating high likelihood that Alcon will soon also be merged with the new parent company.
|This article contains content that is written like an advertisement. (June 2009)|
Alcon was founded in 1945 in Fort Worth, Texas, USA. The company started as a small pharmacy in Fort Worth and was named for its founders, pharmacists Robert Alexander and William Conner. Conner and Alexander focused on sterile ophthalmic products, which no other company specialized in at the timeand built their business by researching eye care products that would reduce contamination and increase safety.
Nestlé of Switzerland purchased Alcon in 1977. This was during a time of rapid growth for Nestlé and was their first venture into the pharmaceutical industry. Alcon expanded its manufacturing capability with new plants in South America and Europe and drastically increased its investment in research. In 1979, Alcon acquired Texas Pharmacal Company which became Dermatological Products of Texas (and is now DPT Laboratories). In 1984, Alcon founded the Technical Excellence Award to promote achievements in R&D excellence and has extended the award to more than 100 recipients. In the 80s and 90s, Alcon continued to grow and became the largest and most profitable ophthalmic company in the world. The Alcon product line has expanded from pharmaceuticals to the surgical arena. The Acrysof intraocular lens is the most commonly used implant in cataract surgery worldwide. Today, Alcon has operations in 75 countries and their products are sold in over 180 countries.
Nestlé conducted an initial public offering of 25% of its stake in Alcon in 2002. The stock is traded under the ticker symbol ACL.
In July 2008, Novartis purchased approximately 25% of Nestlé's stake in Alcon, with an option to buy Nestlé's remaining shares beginning in 2010.
Novartis bought 52% stake from Nestlé for $28.1 Billion. This deal brings the total ownership of Novartis to 77%.
Beginning January 2010 Novartis formally announced it will be completing the exercise options for finishing purchasing the rest of Alcon and then promptly continue to exercise merger and takeover of Alcon.
On March 29, 2010, Alcon acquired DUREZOL(TM) and ZYCLORIN(TM) from Sirion Therapeutics. Alcon received regulatory approval to acquire the rights of Durezol emulsion in the US and the global rights, excluding Latin America, for Zyclorin from Sirion Therapeutics.
On June 28, 2010 the Alcon Independent Director Committee announced that Professor Hans Caspar von der Crone, a leading Swiss legal and corporate governance expert, had concluded that a recommendation by the Independent Director Committee is an indispensable first step before the board of Alcon, Inc. can decide on the merger proposal of Novartis AG, a conclusion which refuted Novartis’ public implications that it would be able to unilaterally impose the merger irrespective of the Independent Director Committee’s position once Novartis became Alcon’s majority shareholder. On July 8, 2010 Alcon's independent director committee (IDC) has set up a $50 million litigation trust to ensure company's minority shareholders get the best deal from bidder Novartis AG.
In August 2010, Novartis acquired the remaining 52 percent of Alcon shares that Nestlé owned, completing the second step of the transaction to become Alcon’s majority owner. Nestlé no longer owns any shares in Alcon.
- Scribd - Novartis exercises option and proposes merger
- title= Improving Vision through Innovation Since 1945
- Reuters - Novartis announces offer to buy Nestlé's shares in Alcon[dead link]
- Alcon Acquires Durezol, Zyclorin From Sirion Therapeutics[dead link] Retrieved from MarketWatch on March 29, 2010
- Alcon Sets up trust for litigation between with Novartis to protect minorities
|40x40px||Wikimedia Commons has media related to Alcon.|
- Alcon Official Website
- Alcon : Novartis exercises option and proposes merger
- Novartis needs Alcon directors' OK for buyout
- Swiss Corporate Governance Expert Supports Alcon Independent Director Committee’s Position against Novartis[dead link]